Outcome measures for vulval skin conditions: A systematic review of randomized controlled trials

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 494-501

  Simpson, R C ^a   Thomas, K S ^a   Murphy, R ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; LABORATORY TEST; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MENOPAUSE; META ANALYSIS; OUTCOME ASSESSMENT; PAGET SKIN DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY; SURVIVAL RATE; SYSTEMATIC REVIEW; VULVA CANCER; VULVA DISEASE; VULVA PRURITUS; VULVA TUMOR; VULVAR VESTIBULITIS; VULVITIS; VULVODYNIA;

FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES; TREATMENT OUTCOME; VULVAR DISEASES;

EID: 84883382994     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12391     Document Type: Article

References (51)

1. Harlow BL, Wise LA, Stewart EG,. Prevalence and predictors of chronic lower genital tract discomfort. Am J Obstet Gynecol 2001; 185: 545-50.
2. Lawton S, Littlewood S,. Vulval skin conditions: disease activity and quality of life. J Low Genit Tract Dis 2013; 17: 117-24.
3. Wojnarowska F, Mayou R, Simkin S, et al,. Psychological characteristics and outcome of patients attending a clinic for vulval disease. J Eur Acad Dermatol Venereol 1997; 8: 121-9.
4. COMET Initiative. Core Outcome Measures in Effectiveness Trials. Available at: http://www.comet-initiative.org/ (last accessed 29 May 2013).
5. University of Oxford. Patient reported outcomes measurement group. Available at: http://phi.uhce.ox.ac.uk/ (last accessed 29 May 2013).
6. Charman CR, Venn AJ, Williams HC,. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-19.
7. Centre of Evidence Based Dermatology, University of Nottingham. Research protocol. Available at: http://www.nottingham.ac.uk/scs/divisions/ evidencebaseddermatology/research/projects/index.aspx (last accessed 28 May 2013).
8. Bergeron S, Binik YM, Khalifé S, et al,. A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain 2001; 3: 297-306.
9. Bornstein J, Abramovici H,. Combination of subtotal perineoplasty and interferon for the treatment of vulvar vestibulitis. Gynecol Obstet Invest 1997; 44: 53-6.
10. Bornstein J, Livnat G, Stolar Z, et al,. Pure versus complicated vulvar vestibulitis: a randomized trial of fluconazole treatment. Gynecol Obstet Invest 2000; 50: 194-7.
11. Bornstein J, Tuma R, Farajun Y, et al,. Topical nifedipine for the treatment of localized provoked vulvodynia: a placebo-controlled study. J Pain 2010; 11: 1403-9.
12. Bornstein J, Zarfati D, Goldik Z, et al,. Perineoplasty compared with vestibuloplasty for severe vulvar vestibulitis. Br J Obstet Gynaecol 1995; 102: 652-5.
13. Danielsson I, Torstensson T, Brodda-Jansen G, et al,. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand 2006; 85: 1360-7.
14. Foster DC, Kotok MB, Huang L-S, et al,. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010; 116: 583-93.
15. Munday PE,. Treatment of vulval vestibulitis with a potent topical steroid. Sex Transm Infect 2004; 80: 154-5.
16. Murina F, Bianco V, Radici G, et al,. Transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomised controlled trial. Br J Obstet Gynaecol 2008; 115: 1165-70.
17. Nyirjesy P, Sobel JD, Weitz MV, et al,. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study. Sex Transm Infect 2001; 77: 53-7.
18. Petersen CD, Giraldi A, Lundvall L, et al,. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 2009; 6: 2523-37.
19. Weijmar Schultz WCM, Gianotten WL, Van Der Meijden WI, et al,. Behavioral approach with or without surgical intervention to the vulvar vestibulitis syndrome: a prospective randomized and non-randomized study. J Psychosom Obstet Gynaecol 1996; 17: 143-8.
20. Brown CS, Wan J, Bachmann G, et al,. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J Women Health (Larchmt) 2009; 18: 163-9.
21. Masheb RM, Kerns RD, Lozano C, et al,. A randomized clinical trial for women with vulvodynia: cognitive-behavioral therapy vs. supportive psychotherapy. Pain 2009; 141: 31-40.
22. Bracco GL, Carli P, Sonni L, et al,. Clinical and histologic effects of topical treatments of vulval lichen sclerosus: a critical evaluation. J Reprod Med 1993; 38: 37-40.
23. Burrows LJ, Creasey A, Goldstein AT,. The treatment of vulvar lichen sclerosus and female sexual dysfunction. J Sex Med 2011; 8: 219-22.
24. Cattaneo A, Carli P, De Marco A, et al,. Testosterone maintenance therapy: effects on vulvar lichen sclerosus treated with clobetasol propionate. J Reprod Med 1996; 41: 99-102.
25. D'Antuono A, Bellavista S, Negosanti F, et al,. Dermasilk briefs in vulvar lichen sclerosus: an adjuvant tool. J Low Genit Tract Dis 2011; 15: 287-91.
26. Goldstein AT, Creasey A, Pfau R, et al,. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011; 64: e99-104.
27. Origoni M, Ferrari D, Rossi M, et al,. Topical oxatomide: an alternative approach for the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet 1996; 55: 259-64.
28. Paslin D,. Treatment of lichen sclerosus with topical dihydrotestosterone. Obstet Gynecol 1991; 78: 1046-9.
29. Paslin D,. Androgens in the topical treatment of lichen sclerosus. Int J Dermatol 1996; 35: 298-301.
30. Sideri M, Origoni M, Spinaci L, et al,. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet 1994; 46: 53-6.
31. Naik R, Nixon S, Lopes A, et al,. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2006; 16: 786-90.
32. van Seters M, van Beurden M, ten Kate FJ, et al,. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358: 1465-73.
33. Lagro-Janssen AL, Sluis S,. Effectiveness of treating non-specific pruritus vulvae with topical steroids: a randomized controlled trial. Eur J Gen Pract 2009; 15: 29-33.
34. Origoni M, Garsia S, Sideri M, et al,. Efficacy of topical oxatomide in women with pruritus vulvae. Drugs Exp Clin Res 1990; 16: 591-6.
35. Rajar UD, Majeed R, Parveen N, et al,. Efficacy of aloe vera gel in the treatment of vulval lichen planus. J Coll Physicians Surg Pak 2008; 18: 612-14.
36. Thongprasom K, Luangjarmekorn L, Sererat T, et al,. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21: 456-8.
37. Curnow JS, Barron L, Morrison G, et al,. Vulval algesiometer. Med Biol Eng Comput 1996; 34: 266-9.
38. Marinoff SC, Turner ML,. Vulvar vestibulitis syndrome. Dermatol Clin 1992; 10: 435-44.
39. Rosen R, Brown C, Heiman J, et al,. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208.
40. Nowinski JK, LoPiccolo J,. Assessing sexual behavior in couples. J Sex Marital Ther 1979; 5: 225-43.
41. Derogatis LR, Melisaratos N,. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther 1979; 5: 244-81.
42. Derogatis LR, Rosen R, Leiblum S, et al,. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28: 317-30.
43. Hudson WW,. Index of sexual satisfaction. In: Handbook of Sexuality-Related Measures. (, CM Davis, WL Yarber, R Bauserman, G Schreer, SL Davis, eds), Thousand Oaks, CA: Sage Publications Inc., 1998, 512-13.
44. Chen SC,. Dermatology quality of life instruments: sorting out the quagmire. J Invest Dermatol 2007; 127: 2695-6.
45. Hickey S, Bell H,. Quality of life in the vulvar clinic: a pilot study. J Low Genit Tract Dis 2010; 14: 225-9.
46. Moher D, Hopewell S, Schulz KF, et al,. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
47. Chren MM,. Giving 'scale' new meaning in dermatology: measurement matters. Arch Dermatol 2000; 136: 788-90.
48. Simpson RC, Thomas KT, Murphy R,. Vulval erosive lichen planus: a qualitative investigation of U.K. clinician views and principles of management. Br J Dermatol 2013; 169: 226-7.
49. Tugwell P, Boers M, Brooks P, et al,. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007; 8: 38.
50. Schmitt J, Langan S, Stamm T, et al,. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Investigative Dermatol 2011; 131: 623-30.
51. Turk DC, Dworkin RH, Allen RR, et al,. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106: 337-45.